HEALOME
LIVE

Serial Number

79377294

Owner

Healome Therapeutics Ltd

Attorney

Nicole M. Meyer

Filing Date

Feb 27, 2023

Add to watchlist:

No watchlists yet
View on USPTO

HEALOME Trademark

Serial Number: 79377294 • Registration: 8081459

HEALOME is a trademark filed by Healome Therapeutics Ltd on February 27, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Healome Therapeutics Ltd (2 trademarks)

Birmingham Research Park,

Entity Type: 99

Trademark Details

Filing Date

February 27, 2023

Registration Date

December 30, 2025

Published for Opposition

November 11, 2025

Goods & Services

Scientific and technological services and research and design relating thereto, namely, scientific research in the field of treatment of eye diseases, injuries and conditions, treatment of dermal diseases, injuries and conditions, and in the field of biomaterials science; industrial scientific analysis and research services in the fields of eye care products and wound care products; product research and development services; scientific and technological services and research services relating thereto, namely, scientific research in the field of treatment of eye diseases, eye injuries and eye conditions, treatment of dermal diseases, injuries and conditions, and in the field of biomaterials science; scientific research services for medical, biomedical and therapeutic purposes in the fields of ocular surface diseases, dry eye diseases, ocular surface injury, corneal wounds, glaucoma; medical and bioscience research services in the fields of ocular surface diseases, dry eye diseases, ocular surface injury, corneal wounds, glaucoma; biomedical research services; scientific research and development services relating to ocular diseases, treatment and conditions; research and development services relating to orthopaedics; scientific research and development services relating to dermatology; scientific research and development services relating to dermal applications, such as scar prevention, wound healing, medical aesthetics; scientific research and development services relating to the treatment of diseases and conditions; scientific research services relating to the treatment of eye diseases and conditions; therapeutic research services, namely, scientific research in the field of eye diseases and eye injury; advisory, consultancy and information services relating to all the aforesaid.

Pharmaceutical preparations and substances and therapeutic pharmaceuticals for diseases, traumatic injury, perioperative care, and inflammation related to the eye; pharmaceutical preparations, substances and treatments in the nature of eye drops, solutions, gels, films impregnated with preparations for the treatment of ocular and dermal conditions, sterilized dressings, sprays, lubricants, and ointments used for treatment for ocular diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of eye drops, solutions, gels, lubricants, and ointments used for treatment for ocular diseases, ocular surface diseases and dry eye disease; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of solutions, gels, films impregnated with preparations for the treatment of ocular and dermal conditions, sterilized dressings, sprays, and ointments used for treatment for dermal diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of solutions, gels, films impregnated with preparations for the treatment of scars, wounds and orthopaedic conditions, and for use in medical aesthetics treatments, sterilized dressings, sprays, and ointments used for treatment for scar prevention, wound healing, medical aesthetics and orthopaedic conditions; therapeutic preparations and substances, namely, eye drops, ocular lubricants, solutions, gels, films impregnated with preparations for the treatment of ocular diseases, ocular conditions, ocular surface diseases and dry eye disease, sterilized dressings, sprays, lubricants, and ointments for the treatment of ocular diseases, ocular conditions, ocular surface diseases and dry eye disease; gels for medical eye care; therapeutic gels for medical eye care; gel and liquid drops, sprays, films for use as a delivery agent for drugs and for therapeutic pharmaceuticals, suspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions, and substances in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gels, suspensions, and liquids in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gels, suspensions, liquids, and lubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditions and diseases; tear film substitutes to provide lubrication, provide protection, support homeostasis, and for use as a delivery agent for drugs and supplements in the treatment of ocular conditions; tear film substitutes to provide lubrication, provide protection, support homeostasis, and for use as a delivery agent for drugs and supplements for the treatment of eye conditions and diseases; gels, suspensions, liquids, and lubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditions, namely, glaucoma, cataracts, amblyopia, age-related macular degeneration and diabetes-related retinopathy; gels, suspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticals, and liquids for medical and therapeutic use, namely, for treating eye diseases, treating traumatic eye injury, and used in perioperative eye care; eye drops; eye ointment for medical use; medicated eye-washes; eye lotions for medical use; lubricating eye drops; medicated liquids for the treatment of ocular diseases and conditions; medicated ocular lubricants; tear film substitutes being pharmaceutical preparations for the treatment of ocular diseases, injuries and conditions; tear substitutes, namely, artificial tears for ocular diseases and conditions; tear film substitutes, being pharmaceutical preparations in the form of eye drops, solutions, gels, sprays, lubricants, ointments and artificial tears for treatment of ocular diseases and conditions

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
May 7, 2026 NREP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 30, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 30, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 30, 2025 R.PR
NEW REPRESENTATIVE AT IB RECEIVED
Nov 29, 2025 NREP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 11, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 11, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 5, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 10, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 10, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 10, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 10, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 10, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 10, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 10, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 10, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 11, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 11, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 11, 2025 CNRT
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 8, 2025 OPNX
ASSIGNED TO EXAMINER
Feb 4, 2025 DOCK
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 22, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 22, 2025 OPNR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 9, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 9, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jan 9, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 9, 2024 GNFN
FINAL REFUSAL E-MAILED
Jul 9, 2024 GNFR
FINAL REFUSAL WRITTEN
Jul 9, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 4, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 4, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 4, 2024 TROA
REFUSAL PROCESSED BY IB
Jan 3, 2024 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 8, 2023 RFCS
REFUSAL PROCESSED BY MPU
Dec 5, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 5, 2023 RFCR
NON-FINAL ACTION WRITTEN
Dec 4, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 28, 2023 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 31, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 31, 2023 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 31, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 31, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 31, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 31, 2023 COAR
APPLICATION FILING RECEIPT MAILED
Aug 29, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 25, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 24, 2023 REPR